September 23, 2008 – CryoLife Inc. announced yesterday that its Hemostase MPH, used to control bleeding in general, cardiac and vascular surgery, is now distributed in Canada through Sorin Group Canada Inc.
Hemostase MPH is developed using Microporous Polysaccharide Hemospheres technology (MPH), which produces a plant-based powder that reportedly rapidly dehydrates blood, and enhances clotting on contact. The Hemostase MPH product received Health Canada approval in 2002, CE Mark approval in 2003 and FDA pre-market approval in 2006.

September 23, 2008 - Digirad Corp. yesterday announced FDA clearance of its nSPEED reconstruction software, to be used in its imaging systems for SPECT procedures at either half-time and/or half count densities with parallel and non-parallel hole collimators, reportedly resulting in quicker exams, improved image quality and less radiation exposure.

September 23, 2008 – Results of the SADHART (Safety and Efficacy of Sertraline for Depression in Patients with CHF) clinical trial were presented yesterday at the 12th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Toronto, presenting evidence of how treatment can improve depression and morbidity in heart failure.

September 22, 2008 - New data on the Edwards SAPIEN transcatheter heart valve with the Ascendra transapical delivery system was presented at the 22nd annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS) in Lisbon, Portugal.

Interim follow-up results from the pre-commercial transapical PARTNER EU registry of 67 transapical patients were presented on Sept. 13 and showed a 30-day survival of 82 percent and a six-month survival of 56 percent. PARTNER EU is a European registry conducted primarily in 2007 that represents Edwards’ early transapical experience.

September 22, 2008 - The American College of Cardiology has certified the LUMEDX Export to CARE Registry solution, part of its integrated cardiovascular imaging and information system, as an ACC-NCDR CARE Registry software vendor.

The Export to CARE Registry solution is the latest in a suite of software applications developed to address the growing need for accessible vascular data, streamlined clinical workflows, and superior data management.

September 22, 2008 - GE Healthcare demonstrated a new diagnostic tool for heart failure called SyncTool by Syntermed on its GE Xeleris 2 workstations at the American Society of Nuclear Cardiology, Sept. 10-14, in Boston.

September 19, 2008 – Volcano Corp. will host “The Future of Intravascular Imaging” symposium Tuesday evening, Oct. 14 at the Renaissance Hotel Convention Center, Washington, D.C., in conjunction with Transcatheter Cardiovascular Therapeutics' annual meeting.

The symposium will address how IVUS, FFT, VH IVUS, CTO imaging and OCT can improve everyday outcomes. Featured speakers include: Alex Abizaid, M.D., Giulio Guagliumi, M.D., Mort Kern, M.D., Steve Marso, M.D, Gary Mintz, M.D., Gus Pichard, M.D., Matt Price, M.D. and David Williams, M.D.

September 19, 2008 - Boston Scientific Corp. announced this week a decision by the U.S. District Court in Delaware involving a case patent owned by Johnson & Johnson and Boston Scientific's NIR stent product.
In the decision, the Judge granted Johnson & Johnson's motion for entry of final judgment and denied Boston Scientific's motion for a new trial.
In 2000, a jury awarded Johnson & Johnson $324 million in damages based on Boston Scientific's sale of the NIR stent. The Court also awarded pre-judgment interest at prime rate based on after-tax damages.

September 19, 2008 – Last month, MIV announced continued positive results for VESTAsync, a polymer-free drug-eluting stent, at a twelve-month clinical follow-up for fifteen patients in its first-in-man VESTASYNC I Trial, reporting that all patients remain free of any major adverse cardiac events or MACE.
MIV also announced that it now has accumulated nine-month intravascular ultrasound (IVUS) and Quantitative Coronary Angiography (QCA) for these same patients. This data showed no statistical difference from the safety and efficacy data reported at four months.

September 19, 2008 - The Larry King Cardiac Foundation and Rush University Medical Center, Chicago, have partnered to provide life-saving cardiac care for patients who have no insurance or limited means, bringing critical care to people who have no other options.
Rush cardiologists and heart surgeons will donate their time and perform surgeries at no cost to the patient, while the Foundation provides funding to compensate the hospital for the materials used.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now